BR0006403A - Stable prolonged-release oral dosage composition - Google Patents

Stable prolonged-release oral dosage composition

Info

Publication number
BR0006403A
BR0006403A BR0006403-3A BR0006403A BR0006403A BR 0006403 A BR0006403 A BR 0006403A BR 0006403 A BR0006403 A BR 0006403A BR 0006403 A BR0006403 A BR 0006403A
Authority
BR
Brazil
Prior art keywords
hours
oral dosage
composition
release oral
dosage composition
Prior art date
Application number
BR0006403-3A
Other languages
Portuguese (pt)
Inventor
Jim H Kou
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0006403(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0006403A publication Critical patent/BR0006403A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toys (AREA)
  • Cosmetics (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO DE DOSAGEM ORAL DE LIBERAçãO PROLONGADA ESTáVEL"<D>. Uma composição de dosagem oral sólida de liberação prolongada e revestida por filme contendo um descongestionante nasal, pseudoefe-drina ou um sal seu, por exemplo o sulfato de pseudoefedrina, em um núcleo efetivo para fornecer uma concentração de pseudoefedrina plasmática máxima geométrica de cerca de 345 ng/ml a cerca de 365 ng/ml em um tempo de cerca de 7,60 horas a cerca de 8,40 horas e apresentando dois ou três revestimentos de filme no núcleo, com o segundo contendo uma quantidade da anti-histamina não sedativa, desloratadina, efetiva para fornecer uma concentração de desloratadina plasmática máxima geométrica de cerca de 2,15 ng/ml a cerca de 2,45 ng/ml em um tempo de cerca de 4,0 horas a cerca de 4,5 horas e o uso da composição para o tratamento de pacientes que apresentam sinais e sintomas associados com condições alérgicas e/ou inflamatórias da pele e das passagens das vias aéreas são revelados.Invention Patent: <B> "STABLE PROLONGED RELEASE ORAL DOSING COMPOSITION" <D>. An extended-release, film-coated solid oral dosage composition containing a nasal decongestant, pseudoephine or a salt thereof, for example pseudoephedrine sulfate, in an effective core to provide a maximum geometric plasma pseudoephedrine concentration of about 345 ng / ml to about 365 ng / ml in a time of about 7.60 hours to about 8.40 hours and having two or three film coatings on the core, with the second containing a quantity of the non-sedating antihistamine , desloratadine, effective to provide a maximum geometric plasma desloratadine concentration of about 2.15 ng / ml to about 2.45 ng / ml in a time of about 4.0 hours to about 4.5 hours and the use of the composition to treat patients who show signs and symptoms associated with allergic and / or inflammatory conditions of the skin and airway passages are revealed.

BR0006403-3A 1999-12-20 2000-12-20 Stable prolonged-release oral dosage composition BR0006403A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17283699P 1999-12-20 1999-12-20

Publications (1)

Publication Number Publication Date
BR0006403A true BR0006403A (en) 2001-07-17

Family

ID=22629437

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0006403-3A BR0006403A (en) 1999-12-20 2000-12-20 Stable prolonged-release oral dosage composition

Country Status (38)

Country Link
US (2) US6979463B2 (en)
EP (2) EP1112738B1 (en)
JP (3) JP5042403B2 (en)
KR (2) KR100936572B1 (en)
CN (3) CN1211079C (en)
AR (1) AR027033A1 (en)
AT (1) ATE463240T1 (en)
AU (4) AU2277101A (en)
BR (1) BR0006403A (en)
CA (1) CA2329217C (en)
CO (1) CO5251435A1 (en)
CY (1) CY1110693T1 (en)
CZ (1) CZ302860B6 (en)
DE (1) DE60044117D1 (en)
DK (1) DK1112738T3 (en)
EC (1) ECSP003836A (en)
EG (1) EG23759A (en)
ES (1) ES2341751T3 (en)
HK (1) HK1034453A1 (en)
HU (1) HUP0004988A3 (en)
ID (1) ID28675A (en)
IL (1) IL140450A (en)
MX (1) MXPA00013037A (en)
MY (1) MY130773A (en)
NO (1) NO331645B1 (en)
NZ (1) NZ509028A (en)
PE (1) PE20010982A1 (en)
PL (1) PL211573B1 (en)
PT (1) PT1112738E (en)
RU (2) RU2303440C2 (en)
SA (2) SA06270069B1 (en)
SG (1) SG109438A1 (en)
SI (1) SI1112738T1 (en)
SK (1) SK287684B6 (en)
TR (1) TR200003787A2 (en)
TW (1) TWI225414B (en)
WO (1) WO2001045668A2 (en)
ZA (1) ZA200007715B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287684B6 (en) 1999-12-20 2011-06-06 Schering Corporation Sustained release solid oral pharmaceutical dosage composition
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
BR0210534A (en) * 2001-06-20 2004-06-22 Schering Corp Antihistamines for the treatment of nasal congestion and nasal obstruction
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
PT1476138E (en) 2002-02-21 2012-02-14 Valeant Internat Barbados Srl Modified release formulations of at least one form of tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US20040229896A1 (en) * 2003-03-12 2004-11-18 Toth Zoltan G. Stable pharmaceutical compositions of desloratadine
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
JP4999329B2 (en) * 2003-12-01 2012-08-15 武田薬品工業株式会社 Pre-printing method for solid preparation
WO2006047427A1 (en) * 2004-10-25 2006-05-04 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
FR2894143B1 (en) 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa PROLONGED RELEASE COMPOSITION OF THE ACTIVE INGREDIENTS, PROCESS FOR PREPARING THE SAME AND USE THEREOF
TWI411451B (en) * 2006-06-01 2013-10-11 Msd Consumer Care Inc Phenylephrine pharmaceutical formulations and compositions for colonic absorption
AU2007254819A1 (en) * 2006-06-01 2007-12-13 Schering Corporation Phenylphrine pulsed release formulations and pharmaceutical compositions
EP2029114B1 (en) * 2006-06-01 2014-09-24 Merck Sharp & Dohme Corp. Pharmaceutical compositions for sustained release of phenylephrine
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
AU2007272951A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2008150493A1 (en) * 2007-06-01 2008-12-11 Schering-Plough Healthcare Products, Inc. Pharmaceutical composition comprising a substrate and a coating containing an active ingredient and polyvinylalcohol
PE20091084A1 (en) * 2007-12-07 2009-07-23 Schering Plough Healthcare PHARMACEUTICAL FORMULATIONS OF PHENYLPHRINE AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2010143202A1 (en) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition
TR201009396A2 (en) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadine granules
DE102016107760B4 (en) 2016-04-26 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Edible functional coatings and hybrid polymer based coatings for pharmacy and food
US20180187263A1 (en) 2017-01-05 2018-07-05 Iowa State University Research Foundation, Inc. Kits for diagnostic detection and prevention of feedlot bovine respiratory disease
EP4188339A1 (en) 2020-07-30 2023-06-07 Faes Farma, S.A. Decongestant drug delivery system

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) 1870-02-22 Improved sun-bonnet for horses
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
WO1985003707A1 (en) 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
SE8404467D0 (en) 1984-09-06 1984-09-06 Ferrosan Ab CONTROLLED-RELEASE MEDICAL PREPARATIONS
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (en) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd Stabilized composition
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
IL98572A (en) 1990-06-22 1995-07-31 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compositions an methods of use
AU665341B2 (en) 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
PT100502A (en) 1991-05-20 1993-08-31 Alza Corp PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE CAPACITY OF PERMEACAO IN THE SKIN USING GLYCEROL MONOLINOLEATE
YU48263B (en) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. PROCEDURE FOR OBTAINING PANTOPRAZOLE PHARMACEUTICAL PRODUCT
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
ES2042421B1 (en) 1992-05-22 1994-08-01 Uriach & Cia Sa J PROCEDURE FOR OBTAINING 8-CHLORINE-11- * 1 - * (5-METHYL-3-PIRIDIL) METHYL * -4-PIPERIDILIDEN * -6,11-DIHYDRO-5H-BENZO * 5,6 * CYCLOHEPTA * 1 , 2-B * PIRIDINE.
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
IT1264517B1 (en) 1993-05-31 1996-09-24 Ekita Investments Nv PHARMACEUTICAL TABLET SUITABLE FOR THE RELEASE IN SUBSEQUENT TIMES OF THE ACTIVE PRINCIPLES CARRIED THEREIN
JP2646972B2 (en) 1993-11-01 1997-08-27 日本電気株式会社 Multi-bit memory
DE4442999A1 (en) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmaceutical composition containing an active loratidine metabolite
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
CN1235545A (en) * 1996-10-31 1999-11-17 先灵公司 Composition, for treatment of asthma, containing loratadine and decongestant
PE71699A1 (en) * 1997-02-07 1999-08-03 Sepracor Inc PHARMACEUTICAL COMPOSITION OF DECARBOETOXYLORATADINE WITHOUT LACTOSE, NON-HYGROSCOPIC AND ANHYDRA
US5900421A (en) 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
US6270796B1 (en) 1997-10-29 2001-08-07 Robert E. Weinstein Antihistamine/decongestant regimens for treating rhinitis
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
ID28645A (en) 1998-07-10 2001-06-21 Schering Corp ORAL COMPOSITIONS 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENA) - 5H-BENZO (5,6) CYCLOHEPTA (1,2-b) PYRIDINE
US6423721B1 (en) 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6051585A (en) 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
SK287684B6 (en) 1999-12-20 2011-06-06 Schering Corporation Sustained release solid oral pharmaceutical dosage composition
EP1251851A1 (en) 2000-02-03 2002-10-30 Schering Corporation Treating allergic and inflammatory conditions
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
CN1173697C (en) 2000-05-19 2004-11-03 爱尔康公司 Aniline disulfide derivatives for treating allergic diseases
US6599913B1 (en) 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions

Also Published As

Publication number Publication date
ECSP003836A (en) 2002-02-25
EP1112738A2 (en) 2001-07-04
ID28675A (en) 2001-06-21
CO5251435A1 (en) 2003-02-28
HUP0004988A3 (en) 2008-04-28
US20030086971A1 (en) 2003-05-08
US6979463B2 (en) 2005-12-27
JP2012224642A (en) 2012-11-15
AU2277101A (en) 2001-07-03
IL140450A (en) 2011-11-30
HUP0004988A2 (en) 2002-11-28
ZA200007715B (en) 2001-06-20
HK1034453A1 (en) 2001-10-26
PT1112738E (en) 2010-06-04
CN1211079C (en) 2005-07-20
CY1110693T1 (en) 2015-06-10
SI1112738T1 (en) 2010-07-30
WO2001045668A2 (en) 2001-06-28
RU2423106C2 (en) 2011-07-10
RU2303440C2 (en) 2007-07-27
SA01210741A (en) 2005-12-03
SK19672000A3 (en) 2001-09-11
WO2001045668A3 (en) 2001-12-13
CZ302860B6 (en) 2011-12-21
PL344715A1 (en) 2001-07-02
TR200003787A3 (en) 2001-07-23
JP2001172174A (en) 2001-06-26
US20060159761A1 (en) 2006-07-20
PE20010982A1 (en) 2001-09-28
NO20006504L (en) 2001-06-21
DK1112738T3 (en) 2010-06-28
NO331645B1 (en) 2012-02-13
NO20006504D0 (en) 2000-12-20
EP2196195A3 (en) 2012-02-29
US7820199B2 (en) 2010-10-26
AU781924B2 (en) 2005-06-23
EP1112738A3 (en) 2001-07-18
DE60044117D1 (en) 2010-05-20
AR027033A1 (en) 2003-03-12
CA2329217C (en) 2006-10-31
SG109438A1 (en) 2005-03-30
MY130773A (en) 2007-07-31
CN101081224B (en) 2012-05-30
EP2196195A2 (en) 2010-06-16
CZ20004812A3 (en) 2001-08-15
NZ509028A (en) 2002-12-20
SA01210741B1 (en) 2006-10-31
IL140450A0 (en) 2002-02-10
RU2007104095A (en) 2008-08-10
CN101081224A (en) 2007-12-05
ATE463240T1 (en) 2010-04-15
PL211573B1 (en) 2012-05-31
CN1679569A (en) 2005-10-12
ES2341751T3 (en) 2010-06-28
AU2009200460B2 (en) 2012-01-19
CA2329217A1 (en) 2001-06-20
AU2009200460A1 (en) 2009-02-26
SA06270069B1 (en) 2009-06-07
RU2423106C9 (en) 2012-06-27
AU7244300A (en) 2001-06-21
JP5042403B2 (en) 2012-10-03
KR100936572B1 (en) 2010-01-13
JP2008081510A (en) 2008-04-10
CN1301534A (en) 2001-07-04
TR200003787A2 (en) 2001-07-23
EG23759A (en) 2007-08-08
KR20010062542A (en) 2001-07-07
KR101234940B1 (en) 2013-02-19
EP1112738B1 (en) 2010-04-07
SK287684B6 (en) 2011-06-06
KR20110028326A (en) 2011-03-17
TWI225414B (en) 2004-12-21
AU2005203771A1 (en) 2005-09-15
MXPA00013037A (en) 2003-06-19
HU0004988D0 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
BR0006403A (en) Stable prolonged-release oral dosage composition
NO951527L (en) Stable, extended-release oral dosage formulation
PT1446119E (en) SUBSTANCES CONTAINING IPRATROPIUM AND XYLOMETAZOLIN IN ITS COMPOSITION FOR THE TREATMENT OF THE COMMON CONSTITUTION
BRPI0414435A (en) methods and reagents for the treatment of immunoinflammatory disorders
CY1106430T1 (en) MEDICATIONS FOR INHALATION CONTAINING VITAMINS AND AN ANTICHOLINEPG
WO2003039436A3 (en) Pharmaceutical compositions containing oxybutynin
BR0000003A (en) Azalides and methods of preparing them
BR0012082A (en) Pharmaceutical formulation for administration comprising morphine and its use
BR9909138A (en) Combination for the treatment of alcohol and drug addiction containing an opioid antagonist and a nmda receptor complex modulator
BR0014946A (en) Use of dipyridamole or mopidamol in the manufacture of a drug for the treatment and prevention of fibrin-dependent microcirculatory disorders
BR0207866A (en) Use of flumazenil in the preparation of a drug for the treatment of cocaine addiction
BRPI0415651A (en) methods for treating, preventing, modifying and / or administering fibromyalgia, and for reducing or preventing an adverse effect associated with the administration of a second active ingredient in a fibromyalgia patient, and, pharmaceutical composition.
BR0108261A (en) Use of mirtazapine, method of treating a sleep disorder in an individual, and patient kit for the treatment of sleep disorders
Lee et al. Tepoxalin enhances the activity of an antioxidant, pyrrolidine dithiocarbamate, in attenuating tumor necrosis factor α-induced apoptosis in WEHI 164 cells
BR0111464A (en) Pharmaceutical composition in unit dosage form and method of treating a patient with diabetic nephropathy
BR0009704A (en) Use of osanetant for the preparation of drugs useful in the treatment of mood disorders
BR9801839A (en) Analgesic medication and application of (+) -0-demethyltramadol.
BR9812466A (en) Use of ifn-alfa and amantadine for the treatment of chronic hepatitis C
BR0016654A (en) Compound, method for treating pain, and pharmaceutical composition
BR0016469A (en) Composition to improve the proliferative response during adaptation of the gastrointestinal tract and use in small intestine syndrome
MAJ Ready-Pack
Falk Diagnostic Index Kit Available From The College
Lewis Should Heroin Be Available for Pain?-Reply
Stephen Forte Paracetamol: safety versus toxicity
TH79012A (en) Oral dosage mixtures with stable dose restricted release.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)